Tags

Type your tag names separated by a space and hit enter

Differentially expressed tRFs in CD5 positive relapsed & refractory diffuse large B cell lymphoma and the bioinformatic analysis for their potential clinical use.
Biol Direct 2019; 14(1):23BD

Abstract

BACKGROUND

Patients diagnosed as diffuse large B cell lymphoma (DLBCL) with CD5 positive normally have a worse outcome and poorly respond to the regulatory treatment strategy.

RESULTS

We recently reported differently expressed tRFs and their potential target-genes of tRFs in patients with CD5+ R/R DLBCL. Differently expressed tRFs were detected by Illumina NextSeq instrument and the results were verified by quantitative real-time reverse transcription-PCR. tRF2Cancer database was searched to compared with the results. Further research was performed through bio-informatic analysis including gene ontology (GO) and pathway enrichment analyses, etc. A total of 308 tRFs were identified. Two sequences (AS-tDR-008946, AS-tDR-013492) were chosen for further investigated.

CONCLUSIONS

The results of Bioinformatics analysis revealed that the target genes including NEDD4L and UBA52 and several associated pathways including PI3K/AKT and MAPK/ERK might be involved in the development of CD5+ R/R DLBCL. Our preliminary study on the associated tRFs might provide a valuable measure to explore the pathogenesis and progression of CD5+ R/R DLBCL.

REVIEWERS

This article was reviewed by Zhen Qing Ye, Nagarajan Raju and Jin Zhuang Dou.

Authors+Show Affiliations

Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, No.324, Jingwu Road, Jinan, Shandong, 250021, People's Republic of China.Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, No.324, Jingwu Road, Jinan, Shandong, 250021, People's Republic of China.Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, No.324, Jingwu Road, Jinan, Shandong, 250021, People's Republic of China.Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, No.324, Jingwu Road, Jinan, Shandong, 250021, People's Republic of China.Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, No.324, Jingwu Road, Jinan, Shandong, 250021, People's Republic of China.Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, No.324, Jingwu Road, Jinan, Shandong, 250021, People's Republic of China.Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, No.324, Jingwu Road, Jinan, Shandong, 250021, People's Republic of China.Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, No.324, Jingwu Road, Jinan, Shandong, 250021, People's Republic of China. yujiejiang05@126.com.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31775867

Citation

Qu, Qingyuan, et al. "Differentially Expressed tRFs in CD5 Positive Relapsed & Refractory Diffuse Large B Cell Lymphoma and the Bioinformatic Analysis for Their Potential Clinical Use." Biology Direct, vol. 14, no. 1, 2019, p. 23.
Qu Q, Li Y, Fang X, et al. Differentially expressed tRFs in CD5 positive relapsed & refractory diffuse large B cell lymphoma and the bioinformatic analysis for their potential clinical use. Biol Direct. 2019;14(1):23.
Qu, Q., Li, Y., Fang, X., Zhang, L., Xue, C., Ge, X., ... Jiang, Y. (2019). Differentially expressed tRFs in CD5 positive relapsed & refractory diffuse large B cell lymphoma and the bioinformatic analysis for their potential clinical use. Biology Direct, 14(1), p. 23. doi:10.1186/s13062-019-0255-8.
Qu Q, et al. Differentially Expressed tRFs in CD5 Positive Relapsed & Refractory Diffuse Large B Cell Lymphoma and the Bioinformatic Analysis for Their Potential Clinical Use. Biol Direct. 2019 Nov 27;14(1):23. PubMed PMID: 31775867.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Differentially expressed tRFs in CD5 positive relapsed & refractory diffuse large B cell lymphoma and the bioinformatic analysis for their potential clinical use. AU - Qu,Qingyuan, AU - Li,Ying, AU - Fang,Xiaosheng, AU - Zhang,Lingyan, AU - Xue,Chao, AU - Ge,Xueling, AU - Wang,Xin, AU - Jiang,Yujie, Y1 - 2019/11/27/ PY - 2019/05/24/received PY - 2019/10/25/accepted PY - 2019/11/29/entrez PY - 2019/11/30/pubmed PY - 2019/11/30/medline KW - Bioinformatics KW - DLBCL KW - Hub gene KW - tRFs SP - 23 EP - 23 JF - Biology direct JO - Biol. Direct VL - 14 IS - 1 N2 - BACKGROUND: Patients diagnosed as diffuse large B cell lymphoma (DLBCL) with CD5 positive normally have a worse outcome and poorly respond to the regulatory treatment strategy. RESULTS: We recently reported differently expressed tRFs and their potential target-genes of tRFs in patients with CD5+ R/R DLBCL. Differently expressed tRFs were detected by Illumina NextSeq instrument and the results were verified by quantitative real-time reverse transcription-PCR. tRF2Cancer database was searched to compared with the results. Further research was performed through bio-informatic analysis including gene ontology (GO) and pathway enrichment analyses, etc. A total of 308 tRFs were identified. Two sequences (AS-tDR-008946, AS-tDR-013492) were chosen for further investigated. CONCLUSIONS: The results of Bioinformatics analysis revealed that the target genes including NEDD4L and UBA52 and several associated pathways including PI3K/AKT and MAPK/ERK might be involved in the development of CD5+ R/R DLBCL. Our preliminary study on the associated tRFs might provide a valuable measure to explore the pathogenesis and progression of CD5+ R/R DLBCL. REVIEWERS: This article was reviewed by Zhen Qing Ye, Nagarajan Raju and Jin Zhuang Dou. SN - 1745-6150 UR - https://www.unboundmedicine.com/medline/citation/31775867/Differentially_expressed_tRFs_in_CD5_positive_relapsed_&_refractory_diffuse_large_B_cell_lymphoma_and_the_bioinformatic_analysis_for_their_potential_clinical_use_ L2 - https://biologydirect.biomedcentral.com/articles/10.1186/s13062-019-0255-8 DB - PRIME DP - Unbound Medicine ER -